Therapy for minimal residual tumor disease: beta-galactosylceramide inhibits the growth of recurrent HPV16-associated neoplasms after surgery and chemotherapy.

@article{mov2010TherapyFM,
  title={Therapy for minimal residual tumor disease: beta-galactosylceramide inhibits the growth of recurrent HPV16-associated neoplasms after surgery and chemotherapy.},
  author={Jana {\vS}{\'i}mov{\'a} and Marie Indrov{\'a} and Jana Bieblov{\'a} and Romana Miky{\vs}kov{\'a} and Jan Buben{\'i}k and Milan Reini{\vs}},
  journal={International journal of cancer},
  year={2010},
  volume={126 12},
  pages={2997-3004}
}
Natural killer T (NKT) cells are potent modulators of antitumor immunity. Their protective effects can be achieved upon their activation by glycolipid ligands presented in the context of the CD1d molecule. These CD1d-binding glycolipid antigens have been described as potent therapeutic agents against tumors, infections, as well as autoimmune diseases… CONTINUE READING